MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,747K
Free Cash flow
$1,624K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturity of available-for-sale s...
Net income
Accrued expenses and other
Others
Negative Cash Flow Breakdown
Purchase of available-for-sale s...
Payment of debt
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
8,189
-3,753
13,438
17,673
Depreciation and amortization
2,516
2,584
2,657
8,281
Stock-based compensation
1,953
1,896
1,617
5,327
Deferred income taxes
-
-
3,245
-
Provision for credit loss recovery
0
0
0
-362
Loss on disposal of property and equipment
0
-6
0
-4
Loss on impairment of asset
-
-
0
-
Accounts receivable, net
7,731
-27,325
20,089
1,192
Inventory, net
4,631
3,178
-3,961
752
Prepaid expenses and other
15
-116
718
-393
Other current assets
3
-60
26
139
Accounts payable
-5,061
3,110
-1,330
877
Operating lease assets and liabilities, net
-300
553
539
1,266
Accrued expenses and other
6,651
-11,694
12,875
279
Post-marketing commitment liability
-544
-503
-672
-1,740
Net cash provided by operating activities
1,624
15,416
14,419
9,689
Purchase of property and equipment
0
0
-36
26
Purchase of available-for-sale securities
21,566
24,863
46,937
26,784
Maturity of available-for-sale securities
29,538
27,337
19,924
27,316
Purchase of intangible assets
-
-
0
-
Net cash provided by (used by) investing activities
7,972
2,474
-26,977
506
Net proceeds from shares issued under employee stock plans
0
-
0
0
Payment of debt
11,120
11,110
11,110
11,110
Payment of exit costs
223
222
222
222
Net cash used in financing activities
-11,343
-11,332
-11,332
-11,332
Net increase (decrease) in cash, cash equivalents, and restricted cash
-1,747
6,558
-23,890
-1,137
Cash, cash equivalents and restricted cash, beginning of period
38,284
31,726
55,616
71,310
Cash, cash equivalents and restricted cash, end of period
36,537
38,284
31,726
55,616
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturity of
available-for-sale securities
$29,538K
(19.18%↑ Y/Y)
Net income
$8,189K
Accrued expenses and
other
$6,651K
Depreciation and
amortization
$2,516K
Stock-based compensation
$1,953K
Operating lease assets and
liabilities, net
-$300K
Net cash provided by
(used by) investing...
$7,972K
(182.04%↑ Y/Y)
Net cash provided by
operating activities
$1,624K
(-90.82%↓ Y/Y)
Canceled cashflow
$21,566K
Canceled cashflow
$17,985K
Net increase
(decrease) in cash, cash...
-$1,747K
(88.00%↑ Y/Y)
Canceled cashflow
$9,596K
Purchase of
available-for-sale securities
$21,566K
(-37.34%↓ Y/Y)
Accounts receivable, net
$7,731K
Accounts payable
-$5,061K
Inventory, net
$4,631K
Post-marketing commitment
liability
-$544K
Prepaid expenses and
other
$15K
Other current assets
$3K
Net cash used in
financing activities
-$11,343K
(49.66%↑ Y/Y)
Payment of debt
$11,120K
(-49.95%↓ Y/Y)
Payment of exit costs
$223K
(-49.77%↓ Y/Y)
Buy us a coffee
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)